Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma - Wikidata - wikimedia - TriplyDB

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

http://www.wikidata.org/entity/Q35741739

about

CD8 T Cell-Independent Antitumor Response and Its Potential for Treatment of Malignant Gliomas Immunotherapy for cancer in the central nervous system: Current and future directions Chimeric antigen receptor T-cell therapy for solid tumors Mesothelin-Targeted CARs: Driving T Cells to Solid Tumors Trial Watch: Adoptive cell transfer for oncological indications Adoptive T-cell therapy for cancer: The era of engineered T cells Biomarkers for glioma immunotherapy: the next generation Immune Responses to Epidermal Growth Factor Receptor (EGFR) and Their Application for Cancer Treatment Engineering T Cells to Functionally Cure HIV-1 Infection Smart CARs engineered for cancer immunotherapy Reengineering chimeric antigen receptor T cells for targeted therapy of autoimmune disease History and current state of immunotherapy in glioma and brain metastasis.Highly Specific and Effective Targeting of EGFRvIII-Positive Tumors with TandAb Antibodies.Anti-EGFRvIII Chimeric Antigen Receptor-Modified T Cells for Adoptive Cell Therapy of Glioblastoma.High expression of B7-H6 in human glioma tissues promotes tumor progression Driving CAR T-cells forward Masked Chimeric Antigen Receptor for Tumor-Specific Activation.In situ programming of leukaemia-specific T cells using synthetic DNA nanocarriers.Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.Developing multi-target therapeutics to fine-tune the evolutionary dynamics of the cancer ecosystem.Tuning Sensitivity of CAR to EGFR Density Limits Recognition of Normal Tissue While Maintaining Potent Antitumor Activity.Fully human CD19-specific chimeric antigen receptors for T-cell therapy.Smart CARS: optimized development of a chimeric antigen receptor (CAR) T cell targeting epidermal growth factor receptor variant III (EGFRvIII) for glioblastoma Emerging targets for glioblastoma stem cell therapy Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival.Making Better Chimeric Antigen Receptors for Adoptive T-cell Therapy Epidermal growth factor receptor targeting and challenges in glioblastoma.Immunotherapy in glioblastoma: emerging options in precision medicine Toxicities of chimeric antigen receptor T cells: recognition and management.Prioritization schema for immunotherapy clinical trials in glioblastoma.Recent advances and future of immunotherapy for glioblastoma.Targeting of Aberrant αvβ6 Integrin Expression in Solid Tumors Using Chimeric Antigen Receptor-Engineered T Cells.Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.Chimeric antigen receptor T cells: a novel therapy for solid tumors.Glioblastoma antigen discovery--foundations for immunotherapy.Glioblastoma targeted therapy: updated approaches from recent biological insights.Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors CAR T-cell immunotherapy: The path from the by-road to the freeway?Glioma Subclassifications and Their Clinical Significance.Adoptive T-Cell Therapy for Solid Tumors.

P2860

Q26740520-75763BB9-EED8-4722-A557-4D8A3B9F95CB Q26750765-B7CD63DC-B49D-4EC8-A6C7-EFF182189520 Q26750908-A9020E7A-3195-46E1-8D42-9E60A2BCA119 Q26778759-254AC4C9-221B-4C13-AF35-4FAA0E42A127 Q26785545-81A0B2EB-C9D6-4955-B302-E0CA6849D94B Q26800611-64EC6FE8-1BE3-4316-ADDC-4C08B49A2D8B Q26825496-E8866E96-B101-48DF-870D-3C88B8732E04 Q28069424-6E3B4DA3-E0E2-406A-965B-2D6FD8EF2E81 Q28086801-A3E4051F-5B59-455B-9835-9578E1134873 Q28087236-3EA9150E-EB30-4DC3-9076-90E458C41F33 Q28276800-4ED604D7-C34C-4B42-9828-F817BFB224B2 Q33656811-7B317187-708E-4BDF-A109-00B2B3D5516E Q33721106-6DB4758F-5DFB-42B9-A85E-B9F46114939D Q33795137-AA0C7D49-F77C-4199-AA16-6A28E0A49B42 Q33913978-1954D508-3459-43ED-B7D3-F0BB0835F7DC Q34046505-58AF37B2-B2F4-4882-88DF-9B152F8D0645 Q34047878-5C6C0A1C-547C-4D93-89EE-F63F0B431907 Q34048101-24CA93F7-036C-4718-9141-3F0C90C4F5B9 Q34517676-D3908FB9-4001-410C-97A3-492443BC5DA4 Q36097745-88DDCF52-B6DC-4B9F-898E-DDA41BC05B08 Q36218880-DA1E7816-45CB-4075-8735-A5B974F7006C Q36281920-5A04E3DD-F518-48EF-9ED8-84DCCF672404 Q36474226-B5FFEA37-44AD-4885-8DF2-64E5FA808A4A Q36502009-6BB2D8D9-0E35-4568-BC13-2F274C77E97A Q36821054-5EC0B0E8-E774-4354-BC05-40987F5C5844 Q36830759-0E3DCE54-0EFD-4DF3-A0D2-4C943DD640E6 Q36977684-0F020A57-7812-42F1-A763-B63F583CAED0 Q37050960-EAE31651-B74D-4E7D-B27F-05C57F0956F4 Q37058104-9C362D41-05A5-435F-9FC3-BFDAB5BEB95F Q37078999-6C878625-3C06-474B-88E1-D814AFB74B5F Q37239071-6B5DA192-438B-4544-A58F-191E9B2B8ECA Q37603527-1F30BE6F-4D3D-4B0F-9E9A-00AF785241CD Q37609801-E290D19F-39D0-44B2-B457-B4429C7F9EEA Q37728639-9B938CE8-8335-417F-86D6-89F36B322AA6 Q38516823-C432C654-55D4-4F28-9357-E05134D49576 Q38597700-DB54848F-A92A-4FA5-AE45-190DD9BCF2EC Q38603686-98AB3C5E-88BD-4C78-8C3D-BC11C3991706 Q38632105-A4A0D212-E610-49B8-9D0D-D34205C200BE Q38747746-4239E620-9088-4FF7-AEEC-F4FA703F8D73 Q38754498-46D76F8D-81D9-44A9-B011-F38B8AC1D417

P2860

Rational development and characterization of humanized anti-EGFR variant III chimeric antigen receptor T cells for glioblastoma

http://www.wikidata.org/entity/Q35741739

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

Rational development and chara ...... eptor T cells for glioblastoma

@ast

Rational development and chara ...... eptor T cells for glioblastoma

@en

type

label

Rational development and chara ...... eptor T cells for glioblastoma

@ast

Rational development and chara ...... eptor T cells for glioblastoma

@en

prefLabel

Rational development and chara ...... eptor T cells for glioblastoma

@ast

Rational development and chara ...... eptor T cells for glioblastoma

@en

P1433

Q35741739-8E3063B4-D8DD-4D2A-B546-03C7FFB52160

P1476

Q35741739-C61EA2F2-5B92-4DD6-8AD2-AF7DEAF36D79

P2093

Q35741739-04DDF843-786E-4F35-8A1E-44564C2176A4

Q35741739-179ADF00-D551-4E49-85E2-C8017D49D9A5

Q35741739-17FA6B54-E6A9-4988-9E9D-C48CF417A8DB

Q35741739-1879CC77-04E6-487A-9BF7-E0F7A356C60F

Q35741739-21E575E3-440E-4F3C-BD6F-4C1CC2C4C39A

Q35741739-29735C38-F53F-43F5-924F-B216B79CB4ED

Q35741739-2D051112-63E3-4551-9CC7-AA4E291F107F

Q35741739-398D5E5F-9848-47B1-9F1E-713CA8708DE7

Q35741739-4264A56F-04CF-4CA3-B423-9417DC71A07E

Q35741739-51BC80B9-D272-4379-A0C0-5CC94704D878

P2860

Q35741739-05F579AD-E788-42D6-9B16-741D160BC145

Q35741739-07A7D892-9132-4C6F-A44D-1EDB46D18460

Q35741739-126FDF49-9D83-40CE-819E-0EA8984CC41F

Q35741739-1425065D-A2EB-450B-A58F-F18626286527

Q35741739-1776B164-77A9-42C4-A884-2B033B61AD8F

Q35741739-22416BF0-FAA0-47F0-9025-A09D4A0BF95F

Q35741739-23C61809-7648-48EC-9C77-F1FD703E2540

Q35741739-345F76CA-0AC5-45AA-A409-32D597A7EA07

Q35741739-41A3D503-AF76-4075-BB48-968649894C39

Q35741739-436BFD76-5B1B-4A79-8DAD-BA598E0749AB

P304

Q35741739-975B9E86-BBB6-42B6-B267-1FAC5DA68DE4

P31

Q35741739-F947C764-95EC-491F-8708-06494197A679

P356

Q35741739-B3FF521A-12D9-4E29-960C-2AFB54FAB041

P407

Q35741739-C077996F-3A54-45C6-89B9-01CF1AD10ED5

P433

Q35741739-501EB98A-8B9F-43C0-A9DC-96BA82D1BA06

P478

Q35741739-144FAD89-DC05-40B8-A968-31B09E5E4D4B

P50

Q35741739-5FCB9C8E-D55D-4F72-B7D4-C41FB4146D7F

Q35741739-A97233DB-922A-4511-B7DD-ACE9E2C9482E

P577

Q35741739-FD2F8137-7394-4881-A372-A6EBC1489836

P5875

Q35741739-84A7BD6C-6195-4848-9F6E-44C5F687B23D

P698

Q35741739-4B1C803C-3AB1-45EC-81F4-E7A72A68A5D6

P932

Q35741739-13BBBFAF-D7ED-494E-874B-617F7160D4CC

P356

SCITRANSLMED.AAA4963

P1433

Science Translational Medicine

P1476

Rational development and chara ...... eptor T cells for glioblastoma

@en

P2093

Akemi Kosaka

http://www.w3.org/2001/XMLSchema#string

Alina C Boesteanu

http://www.w3.org/2001/XMLSchema#string

Andreas Loew

http://www.w3.org/2001/XMLSchema#string

Arben K Nace

http://www.w3.org/2001/XMLSchema#string

Avery D Posey

http://www.w3.org/2001/XMLSchema#string

Boris Engels

http://www.w3.org/2001/XMLSchema#string

Carl H June

http://www.w3.org/2001/XMLSchema#string

Christopher C Kloss

http://www.w3.org/2001/XMLSchema#string

Gabriela Plesa

http://www.w3.org/2001/XMLSchema#string

Hideho Okada

http://www.w3.org/2001/XMLSchema#string

P2860

Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1

Chimeric antigen receptor T cells for sustained remissions in leukemia

Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia

Chimeric antigen receptor-modified T cells for acute lymphoid leukemia

P304

275ra22

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1126/SCITRANSLMED.AAA4963

http://www.w3.org/2001/XMLSchema#string

P407

P433

275

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Alexandria P Cogdill

Shannon E McGettigan

P577

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

272517526

http://www.w3.org/2001/XMLSchema#string

P698

25696001

http://www.w3.org/2001/XMLSchema#string

P932

4467166

http://www.w3.org/2001/XMLSchema#string